Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 10/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 10/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445496 | 1.00 | EHMT2 (0.52) | EHMT2EHMT1PDGFRBNCF1PDGFRA | |
| SCHEMBL22455218 | 0.89 | DRD2 (0.48) | EHMT2EHMT1PDGFRBNCF1FLT3 | |
| SCHEMBL29357549 | 0.89 | DRD2 (0.48) | EHMT2EHMT1PDGFRBNCF1FLT3 | |
| SCHEMBL28681217 | 0.89 | DRD2 (0.48) | EHMT2EHMT1PDGFRBNCF1FLT3 | |
| SCHEMBL28685913 | 0.87 | EHMT2 (0.47) | EHMT2EHMT1PDGFRBNCF1PDGFRA | |
| SCHEMBL22455368 | 0.85 | ENPP1 (0.49) | EHMT2EHMT1PDGFRBNCF1 | |
| SCHEMBL35210187 | 0.84 | NCF1 (0.47) | EHMT2EHMT1PDGFRBNCF1PDGFRA | |
| SCHEMBL22445544 | 0.83 | NCF1 (0.54) | EHMT2EHMT1PDGFRBNCF1FLT3 | |
| SCHEMBL22441506 | 0.83 | NCF1 (0.54) | EHMT2EHMT1PDGFRBNCF1FLT3 | |
| SCHEMBL22441504 | 0.83 | NCF1 (0.54) | EHMT2EHMT1PDGFRBNCF1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | Stingray Therapeutics, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299258-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | EHMT2 2342/4885EHMT1 1468/4885PDGFRB 3543/4885 |
| US-11407729-B2 | Quinoline and quinazoline compounds and methods of use thereof | ENPP1, ENPP3, PDE7A | EHMT2 2342/4885EHMT1 1468/4885PDGFRB 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.